Clinical Trial Update: Calcineurin Inhibitor Sparing After Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating strategies to spare calcineurin inhibitors after kidney transplantation to reduce CNI-related side effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Kidney Transplantation

Snippet

Sponsor: University of Minnesota | Conditions: CNI Side Effects | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-14